|
12 Mar 2020 |
BridgeBio Pharma’s QED Therapeutics Announces Dosing of First Patients in Phase 3 and Phase 2 Clinical Trials of Infigratinib in Tumors with FGFR Genetic Alterations
|
|
12 Mar 2020 |
Engage Therapeutics Announces Phase 2b StATES Study of Staccato® Alprazolam for Seizure Cessation Meets Primary Endpoint
|
|
12 Mar 2020 |
Kymera Therapeutics Announces $102 Million Series C Financing to Advance its Protein Degrader Pipeline and Platform
|
|
12 Mar 2020 |
AbbVie Receives European Commission Approval of VENCLYXTO® Combination Regimen for Patients with Previously-Untreated Chronic Lymphocytic Leukemia
|
|
12 Mar 2020 |
New Clinical Study Data for Gilead’s Investigational HIV-1 Capsid Inhibitor GS-6207 Presented at CROI 2020
|
|
12 Mar 2020 |
Update on Phase III GY004 trial for cediranib added to Lynparza in platinum-sensitive relapsed ovarian cancer
|
|
11 Mar 2020 |
Cadent Therapeutics Announces FDA Clearance of IND Application and Dosing of Subjects of CAD-9303 for Schizophrenia
|
|
11 Mar 2020 |
Asana BioSciences Announces Topical Sodium Channel Blocker ASN008 Achieves Positive Results for the Treatment of Pruritus in Atopic Dermatitis; and Provides Update on JAK/SYK Inhibitor Gusacitinib in Phase 2 Studies for Chronic Hand Eczema and AD
|
|
11 Mar 2020 |
MedDay Reports Top-Line Data from Phase III Trial “SPI2” for Treatment of Progressive Forms of Multiple Sclerosis
|
|
11 Mar 2020 |
Treatment With Gilead’s Vesatolimod Is Evaluated for Safety and Virologic and Immunologic Response Versus Placebo in Phase 1B HIV Functional Cure Study
|
|
11 Mar 2020 |
InMed Pharmaceuticals Announces Completed Enrollment in Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects
|
|
11 Mar 2020 |
FDA approves Ofev® as first treatment for chronic fibrosing ILDs with a progressive phenotype
|
|
11 Mar 2020 |
NuCana Reports Preliminary Data from Phase II Study of Single-Agent Acelarin (NUC-1031) in Patients with Platinum-Resistant Ovarian Cancer
|
|
11 Mar 2020 |
Takeda Provides Update on TOURMALINE-MM2 Phase 3 Trial
|
|
10 Mar 2020 |
Athenex Announces FDA Acceptance for Filing of U.S. NDA for Tirbanibulin Ointment in Actinic Keratosis
|
|
10 Mar 2020 |
Myovant Sciences Submits Marketing Authorization Application to the European Medicines Agency for Relugolix Combination Tablet for the Treatment of Women with Uterine Fibroids
|
|
09 Mar 2020 |
ViiV Healthcare presents positive 48-week data from phase III study showing every-two-month regimen of investigational long-acting, injectable cabotegravir and rilpivirine has similar efficacy to once-monthly dosing
|
|
09 Mar 2020 |
AbbVie Partnering with Global Authorities to Determine Efficacy of HIV Drug in Treating COVID-19
|
|
09 Mar 2020 |
Zhimeng Biopharma Announces the First-in-Human Dosing in Phase I Clinical Trial of ZM-H1505R Designed for the Treatment of Chronic Hepatitis B Virus Infection
|
|
08 Mar 2020 |
Shionogi and Tetra Therapeutics Entered into New Strategic Collaboration for BPN14770, the Drug Candidates for the Treatment of Brain Disorders Marked by Cognitive and Memory Deficits
|
|
08 Mar 2020 |
FDA Approves New Treatment for Adults with Cushing’s Disease
|
|
08 Mar 2020 |
European Commission Grants AbbVie Marketing Authorization Shortening MAVIRET® (glecaprevir/pibrentasvir) Treatment Duration to Eight Weeks for Treatment-Naïve Chronic HCV Patients with Genotype 3 and Compensated Cirrhosis
|
|
05 Mar 2020 |
Debiopharm Advances into the Highly Anticipated Clinical Phase for their Potent WEE1 Inhibitor
|
|
05 Mar 2020 |
BioCryst Begins Proof of Concept Trial in PNH Patients With Oral Factor D Inhibitor, BCX9930
|
|
04 Mar 2020 |
Scientists from Merck and the Walter and Eliza Hall Institute of Medical Research Discover Novel Class of Candidate Anti Malaria Agents that Block Multiple Stages of the Lifecycle of the Parasite
|
